
## Mariano Santaquilani

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6761322/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Clinical and Immunological Outcomes in High-Risk Resected Melanoma Patients Receiving Peptide-Based Vaccination and Interferon Alpha, With or Without Dacarbazine Preconditioning: A Phase II Study. Frontiers in Oncology, 2020, 10, 202.	1.3	6
2	Treatment challenges in and outside a network setting: Soft tissue sarcomas. European Journal of Surgical Oncology, 2019, 45, 31-39.	0.5	27
3	Epidemiology of rare cancers and inequalities in oncologic outcomes. European Journal of Surgical Oncology, 2019, 45, 3-11.	0.5	47
4	Treatment challenges in and outside a specialist network setting: Pancreatic neuroendocrine tumours. European Journal of Surgical Oncology, 2019, 45, 46-51.	0.5	3
5	Mesothelioma and thymic tumors: Treatment challenges in (outside) a network setting. European Journal of Surgical Oncology, 2019, 45, 75-80.	0.5	15
6	Testicular germ-cell tumours and penile squamous cell carcinoma: Appropriate management makes the difference. European Journal of Surgical Oncology, 2019, 45, 60-66.	0.5	4
7	Treatment challenges in and outside a network setting: Head and neck cancers. European Journal of Surgical Oncology, 2019, 45, 40-45.	0.5	27
8	Burden and centralised treatment in Europe of rare tumours: results of RARECAREnet—a population-based study. Lancet Oncology, The, 2017, 18, 1022-1039.	5.1	285
9	Changes in dynamics of excess mortality rates and net survival after diagnosis of follicular lymphoma or diffuse large B-cell lymphoma: comparison between European population-based data (EUROCARE-5). Lancet Haematology,the, 2015, 2, e481-e491.	2.2	33
10	Age and case mix-standardised survival for all cancer patients in Europe 1999–2007: Results of EUROCARE-5, a population-based study. European Journal of Cancer, 2015, 51, 2120-2129.	1.3	66
11	The EUROCARE-5 study on cancer survival in Europe 1999–2007: Database, quality checks and statistical analysis methods. European Journal of Cancer, 2015, 51, 2104-2119.	1.3	97
12	Cancer survival in Europe 1999–2007 by country and age: results of EUROCARE-5—a population-based study. Lancet Oncology, The, 2014, 15, 23-34.	5.1	1,554
13	Survival for haematological malignancies in Europe between 1997 and 2008 by region and age: results of EUROCARE-5, a population-based study. Lancet Oncology, The, 2014, 15, 931-942.	5.1	229
14	Childhood cancer survival in Europe 1999–2007: results of EUROCARE-5—a population-based study. Lancet Oncology, The, 2014, 15, 35-47.	5.1	799
15	Cancer prevalence estimates in Europe at the beginning of 2000. Annals of Oncology, 2013, 24, 1660-1666.	0.6	36
16	Survival and cure trends for European children, adolescents and young adults diagnosed with acute lymphoblastic leukemia from 1982 to 2002. Haematologica, 2013, 98, 744-752.	1.7	35
17	Survival for Ovarian Cancer in Europe: The across-country variation did not shrink in the past decade. Acta Oncológica, 2012, 51, 441-453.	0.8	88
18	Oesophageal cancer survival in Europe: A EUROCARE-4 study. Cancer Epidemiology, 2012, 36, 505-512.	0.8	108

Mariano Santaquilani

#	Article	IF	CITATIONS
19	Progress in colorectal cancer survival in Europe from the late 1980s to the early 21st century: The EUROCARE study. International Journal of Cancer, 2012, 131, 1649-1658.	2.3	216
20	Survival of European patients with central nervous system tumors. International Journal of Cancer, 2012, 131, 173-185.	2.3	64
21	Prognoses for head and neck cancers in Europe diagnosed in 1995–1999: a population-based study. Annals of Oncology, 2011, 22, 165-174.	0.6	35
22	European disparities in malignant digestive endocrine tumours survival. International Journal of Cancer, 2010, 126, 2928-2934.	2.3	57
23	Survival from salivary glands adenoid cystic carcinoma in European populations. Oral Oncology, 2009, 45, 669-674.	0.8	94
24	The EUROCARE-4 database on cancer survival in Europe: Data standardisation, quality control and methods of statistical analysis. European Journal of Cancer, 2009, 45, 909-930.	1.3	120
25	Long-term survival expectations of cancer patients in Europe in 2000–2002. European Journal of Cancer, 2009, 45, 1028-1041.	1.3	87
26	The advantage of women in cancer survival: An analysis of EUROCARE-4 data. European Journal of Cancer, 2009, 45, 1017-1027.	1.3	233
27	EUROCARE-4. Survival of cancer patients diagnosed in 1995–1999. Results and commentary. European Journal of Cancer, 2009, 45, 931-991.	1.3	740
28	The cancer survival gap between elderly and middle-aged patients in Europe is widening. European Journal of Cancer, 2009, 45, 1006-1016.	1.3	186
29	Survival trends in European cancer patients diagnosed from 1988 to 1999. European Journal of Cancer, 2009, 45, 1042-1066.	1.3	133
30	Multiple tumours in survival estimates. European Journal of Cancer, 2009, 45, 1080-1094.	1.3	109
31	The cure of cancer: A European perspective. European Journal of Cancer, 2009, 45, 1067-1079.	1.3	80
32	Survival of European children and young adults with cancer diagnosed 1995–2002. European Journal of Cancer, 2009, 45, 992-1005.	1.3	442
33	Comparative cancer survival information in Europe. European Journal of Cancer, 2009, 45, 901-908.	1.3	123
34	Influence of morphology on survival for non-Hodgkin lymphoma in Europe and the United States. European Journal of Cancer, 2008, 44, 579-587.	1.3	32
35	Cancer survival in five continents: a worldwide population-based study (CONCORD). Lancet Oncology, The, 2008, 9, 730-756.	5.1	1,059
36	Survival in Patients With Uveal Melanoma in Europe. JAMA Ophthalmology, 2008, 126, 1413.	2.6	95

#	Article	IF	CITATIONS
37	Life Tables for World-Wide Comparison of Relative Survival for Cancer (CONCORD Study). Tumori, 2008, 94, 658-668.	0.6	36
38	Multicenter Comparative Multimodality Surveillance of Women at Genetic-Familial High Risk for Breast Cancer (HIBCRIT Study): Interim Results. Radiology, 2007, 242, 698-715.	3.6	324
39	Survival for eight major cancers and all cancers combined for European adults diagnosed in 1995–99: results of the EUROCARE-4 study. Lancet Oncology, The, 2007, 8, 773-783.	5.1	718
40	EUROCARE-3: survival of cancer patients diagnosed 1990–94—results and commentary. Annals of Oncology, 2003, 14, v61-v118.	0.6	638
41	EUROCARE-3 summary: cancer survival in Europe at the end of the 20th century. Annals of Oncology, 2003, 14, v128-v149.	0.6	400
42	Mortality from Cancer and Other Causes among Airline Cabin Attendants in Europe: A Collaborative Cohort Study in Eight Countries. American Journal of Epidemiology, 2003, 158, 35-46.	1.6	88
43	Electronic availability of EUROCARE-3 data: a tool for further analysis. Annals of Oncology, 2003, 14, v150-v155.	0.6	28
44	The EUROCARE-3 database: methodology of data collection, standardisation, quality control and statistical analysis. Annals of Oncology, 2003, 14, v14-v27.	0.6	74
45	Radiation-induced health effects on atmospheric flight crew members: clues for a radiation-related risk analysis. Advances in Space Research, 2002, 30, 1017-1020.	1.2	4
46	A Retrospective Cohort Mortality Study of Italian Commercial Airline Cockpit Crew and Cabin Attendants, 1965–96. International Journal of Occupational and Environmental Health, 2002, 8, 87-96.	1.2	21
47	A Retrospective Cohort Mortality Study of Italian Commercial Airline Cockpit Crew and Cabin Attendants, 1965–96. International Journal of Occupational and Environmental Health, 2002, 8, 87-96.	1.2	20
48	Survival of children with Wilms' tumour in Europe. European Journal of Cancer, 2001, 37, 736-743.	1.3	14
49	Radiation exposure of airline crew members to the atmospheric ionizing radiation environment. Radiation Physics and Chemistry, 2001, 61, 655-657.	1.4	2
50	Health Risks from Radiation Exposure for Civilian Aviation Flight Personnel: A Study of Italian Airline Crew Members. Radiation Research, 2001, 156, 689-694.	0.7	7